JLS Fund

Immunis is a private biotechnology company focused on addressing age and disease-related immune decline through innovative stem cell-derived therapies. The company specializes in utilizing human stem cells to create specific populations of cells that secrete therapeutic factors. This approach aims to enable healthcare professionals to enhance immune system development, modulation, and overall health in patients. By harnessing the potential of stem cell technology, Immunis seeks to offer novel treatment options that can improve immune function and combat the effects of aging and various diseases.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York, focused on developing innovative psychotropic drugs to address mental health issues. Founded in 2019, the company specializes in creating novel compounds that enhance the benefits of traditional psychedelics, improving parameters such as safety, tolerability, duration, and efficacy. Gilgamesh targets a range of neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. With the growing global mental health crisis, the company aims to accelerate the development of new treatments that meet the urgent need for effective solutions in mental health care, leveraging its expertise in medicinal chemistry and drug development.

Homecoming is a provider of patient engagement tools specifically designed for psychedelic therapy. The company has developed a digital companion application that supports patients throughout their therapeutic process. This application promotes accountability and fosters long-term change by offering personalized guides, tasks, and daily check-ins. Additionally, it provides preparation and integration support within a single, user-friendly platform that includes relevant patient program content. This enables healthcare professionals to effectively guide their patients on their healing journeys, enhancing the therapeutic experience and outcomes.

Fluence offers continuing education and certificate programs in psychedelic integration and psychedelic-assisted therapy. Our programs are designed for licensed professionals and advanced graduate students who have an opportunity to work with patient populations. Although none of our courses have specific prerequisites, a basic working knowledge of the mental health field and practice of psychotherapy is helpful. Our programs are interactive; we engage in discussion, demonstration, self-reflection exercises, and role plays. Some of our classes and programs are reserved for licensed clinicians, but many are open to anyone who wishes to attend.

Psilera is a biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases through the use of psychedelic compounds. The company focuses on creating a new class of neurological medicines, with its lead asset, PSIL-006, being a non-hallucinogenic derivative of psilocybin aimed at treating frontotemporal dementia. Psilera’s approach involves repurposing psychoactive natural products as foundational elements for next-generation therapies that enhance mental health. By prioritizing scientific excellence, Psilera seeks to transform the lives of individuals affected by cognitive, mood, and substance use disorders, marking a significant advancement in the field of mindful medicine.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York, focused on developing innovative psychotropic drugs to address mental health issues. Founded in 2019, the company specializes in creating novel compounds that enhance the benefits of traditional psychedelics, improving parameters such as safety, tolerability, duration, and efficacy. Gilgamesh targets a range of neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. With the growing global mental health crisis, the company aims to accelerate the development of new treatments that meet the urgent need for effective solutions in mental health care, leveraging its expertise in medicinal chemistry and drug development.

WeSana Health is a life sciences company focused on the advancement of psilocybin-based medicine. Founded in 2020 by Daniel Carcillo, the company is headquartered in Homer Glen, Illinois. WeSana Health is actively exploring new business opportunities to further its mission in the burgeoning field of psychedelics, aiming to develop innovative therapeutic solutions for various mental health conditions.